Consensus statement of the Russian Society of Obstetricians and Gynecologists and the Russian Association of Mammologists on the effect of combined oral contraceptives on breast tissue
- Issue: No 6 (2024)
- Pages: 177-181
- Section: Clinical Notes
- URL: https://journals.eco-vector.com/0300-9092/article/view/634475
- DOI: https://doi.org/10.18565/aig.2024.148
- ID: 634475
Cite item
Open Access
Access granted
Full Text
References
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Доброкачественная дисплазия молочной железы. 2020. [Ministry of Health of the Russian Federation. Clinical guidelines. Benign breast dysplasia. 2020. (in Russian)].
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак молочной железы. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Breast cancer. 2021. (in Russian)].
- Сухих Г.Т., Прилепская В.Н., ред. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015». М.; 2023. [Sukhikh G.T., Prilepskaya V.N., ed. National medical acceptance criteria for contraceptive methods. Adapted from WHO Medical Acceptance Criteria for Contraceptive Use, 5th Edition, 2015. Moscow; 2023. (in Russian)].
- Burkman R.T. Oral contraceptives: current status. Clin. Obstet. Gynecol. 2001; 44(1): 62-72. https://dx.doi.org/10.1097/00003081-200103000-00010.
- Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int. J. Endocrinol. Metab. 2013; 11(1): 41-7. https://dx.doi.org/10.5812/ijem.4158.
- Royal College of General Practitioners’ Oral Contraception Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet. 1977; 1(8012): 624.
- Brinton L.A., Vessey M.P., Flavel R., Yeates D. Risk factors for benign breast disease. Am. J. Epidemiol. 1981; 113(3): 203-14. https://dx.doi.org/10.1093/oxfordjournals.aje.a113089.
- Леонидова Т.Н., Микова В.Н. Гормональная контрацепция и маммологические риски. Доктор.Ру. 2016; 3(120): 15-7. [Leonidova T.N., Mikova V.N. Hormonal contraception and risks for breast disorders. Doctor.Ru. 2016; 3(120): 15-7. (in Russian)].
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996; 347(9017): 1713-27. https://dx.doi.org/10.1016/s0140-6736(96)90806-5.
- Iversen L., Sivasubramaniam S., Lee A.J., Fielding S., Hannaford P.C. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am. J. Obstet. Gynecol. 2017; 216(6): 580.e1-580.e9. https://dx.doi.org/10.1016/j.ajog.2017.02.002.
- Barańska A., Błaszczuk A., Kanadys W., Malm M., Drop K., Polz-Dacewicz M. Oral contraceptive use and breast cancer risk assessment: a systematic review and meta-analysis of case-control studies, 2009-2020. Cancers (Basel). 2021; 13(22): 5654. https://dx.doi.org/10.3390/cancers13225654.
- Адамян Л.В., Котова Е.Г., Родионов В.В., Протасова А.Э., Шешко Е.Л. Роль врача-гинеколога в выявлении патологии молочной железы и сочетанных гиперпролиферативных заболеваний. Проблемы репродукции. 2023; 29(5): 6-17. [Adamyan L.V., Kotova E.G., Rodionov V.V., Protasova A.E., Sheshko E.L. The role of the gynecologist in the detection of breast pathology and coexisting hyperproliferative diseases. Russian Journal of Human Reproduction. 2023; 29(5): 6-17. (in Russian)]. https://dx.doi.org/10.17116/ repro2023290516.
- Gallez A., Dias Da Silva I., Wuidar V., Foidart J.M., Péqueux C. Estetrol and mammary gland: friends or foes? J. Mammary Gland Biol. Neoplasia. 2021; 26(3): 297-308. https://dx.doi.org/10.1007/s10911-021-09497-0.
- Schmidt M., Lenhard H., Hoenig A., Zimmerman Y., Krijgh J., Jansen M. et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 2021; 147(6): 1833-42. https://dx.doi.org/10.1007/s00432-020-03472-8.
- Singer C.F., Bennink H.J., Natter C., Steurer S., Rudas M., Moinfar F. et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014; 35(11): 2447-51. https://dx.doi.org/10.1093/carcin/bgu144.
- Инструкция по медицинскому применению препарата «Эстеретта». [Instructions for medical use of Esteretta. (in Russian)].
- Łukasiewicz S., Czeczelewski M., Forma A., Baj J., Sitarz R., Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021; 13(17): 4287. https://dx.doi.org/10.3390/cancers13174287.
- Tamimi R.M., Spiegelman D., Smith-Warner S.A., Wang M., Pazaris M., Willett W.C. et al. Population Attributable Risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am. J. Epidemiol. 2016; 184(12): 884-93. https://dx.doi.org/10.1093/aje/kww145.
- WHO. Preventing cancer. https://www.who.int/activities/preventing-cancer (last access May, 2024).
- Stewart B.W., Bray F., Forman D., Ohgaki H., Straif K., Ullrich A. et al. Cancer prevention as part of precision medicine: ‘plenty to be done’. Carcinogenesis. 2016; 37(1): 2-9. https://dx.doi.org/10.1093/carcin/ bgv166.
- Сметник А.А., Родионов В.В., Кометова В.В., Бурменская О.В., Дардык М.В., Сенча А.Н., Ермакова Е.И., Ашрафян Л.А. Молочная железа и половые гормоны. Акушерство и гинекология. 2021; 12: 58-66. [Smetnik A.A., Rodionov V.V., Kometova V.V., Burmenskaya O.V., Dardyk M.V., Sencha A.N., Ermakova E.I., Ashrafyan L.A. The breast and sex hormones. Obstetrics and Gynecology. 2021; (12): 58-66. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.12.58-66.
Supplementary files
